Impact of model for end-stage liver disease (MELD) score for mortality in patients undergoing coronary bypass surgery.

OBJECTIVES The aim of the study is to evaluate the predictive value of the model for end-stage liver disease (MELD) score for mortality in stable angina pectoris patients undergoing coronary artery bypass graft (CABG) surgery. METHODS We retrospectively analyzed 261 consecutive patients with stable angina pectoris who underwent CABG while not being on anticoagulant therapy. The patients were divided into two groups: survivors and non-survivors. The MELD score was calculated for all patients. The all-cause mortality within postoperative 12 months was the primary end point of the study. RESULTS The follow-up period was 12 months. The non-survivors were older (72.0±6.1 vs 62.4±8.4, p<0.001). The MELD score was significantly higher in the non-survivors group (7.5±1.2 vs 6.7±0.7, p<0.001). The MELD score (p=0.001) was an independent predictor of postoperative one-year mortality. The addition of MELD score to EuroSCORE II significantly improved the prognostic performance of the EuroSCORE II (EuroSCORE II vs EuroSCORE II plus MELD score: AUCs: 0.792 vs 0.842). CONCLUSION Our research showed that the MELD score could be useful to predict mortality in patients who have stable coronary artery disease, and are undergoing CABG surgery (Tab. 3, Fig. 2, Ref. 25).